# Sacituzumab Tirumotecan Plus Tagitanlimab in Previously Treated Locally Advanced or Metastatic Triple Negative Breast Cancer

Source: https://onco.cc/trials/nct07153965/  
OnCo record `nct07153965` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of sacituzumab tirumotecan in triple-negative breast cancer, run by Tianjin Medical University Cancer Institute and Hospital, not yet recruiting.

## Summary

Sacituzumab Tirumotecan Plus Tagitanlimab in Previously Treated Locally Advanced or Metastatic Triple Negative Breast Cancer is a phase 2, interventional study registered as NCT07153965 by Tianjin Medical University Cancer Institute and Hospital, with a registry enrolment figure of 47 participants, started 2025-09-01 and due to reach its primary completion in 2026-09-01. Interventions recorded: Sacituzumab Tirumotecan plus Tagitanlimab. Conditions listed: Triple Negative Breast Cancer (TNBC); PD-L1 Positive. Triple-negative eligibility wording from the registry: "* Histologically and/or cytologically confirmed triple-negative breast cancer (TNBC) based on the most recent biopsy or other pathological specimens, including:". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT07153965
- Phase: 2
- Setting: An Open-label, Single-arm, Multicenter Phase II Study of Sacituzumab Tirumotecan (Sac-TMT) Plus Tagitanlimab in Previously Treated PD-L1-positive Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)
- Sponsor: Tianjin Medical University Cancer Institute and Hospital
- Enrolled: 47

## Sources

- ClinicalTrials.gov NCT07153965: https://clinicaltrials.gov/study/NCT07153965

## Connected records

- cancers: [Metastatic triple-negative breast cancer](https://onco.cc/cancers/tnbc-metastatic/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)
- drugs: [Sacituzumab tirumotecan](https://onco.cc/drugs/sacituzumab-tirumotecan/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07153965.json